Evaluation of HRPT2 gene abnormalities seems to be a more promising diagnostic tool.(77) Loss of heterozygosity (LOH) or mutation at the HRPT2 gene and loss (total or focal) of parafibromin staining have been reported in the large majority of parathyroid carcinomas but very rarely in adenomas(45,78–81) (Fig. 2). This evidence concerns the gene CDC73 and adenoma.